文献速递造血干细胞移植与细胞治疗

异基因造血干细胞移植后人类疱疹病毒6型感染的临床特征分析

[Clinical characteristics of HHV-6 infection after allogeneic hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

该回顾性研究纳入2016年2月至2023年2月在北京大学血液病研究所接受allo-HSCT后100天内HHV-6阳性的305例患者,分析临床表现及病毒载量、抗病毒治疗与转归的关系。结果显示发热、皮疹、腹泻最常见,病毒滴度与临床表现无显著相关,抗病毒治疗组与未治疗组HHV-6转阴时间及5年OS率均无统计学显著差异。

要点

  • allo-HSCT后100天内HHV-6感染以发热、皮疹、腹泻最多见,15例无症状。
  • 45例有定量检测结果者中,病毒滴度高低与临床表现差异无统计学意义。
  • 抗病毒治疗组与未治疗组HHV-6转阴时间及5年OS率均无统计学显著差异。

核心结论

  • allo-HSCT后HHV-6感染临床表现以发热、皮疹和腹泻多见,与病毒滴度高低无明显相关性,是否抗病毒治疗在HHV-6转阴时间与移植后5年OS率中未见显著性差异。

研究设计与样本

  • 回顾性研究纳入2016年2月至2023年2月在北京大学血液病研究所接受allo-HSCT后100天内HHV-6阳性的305例患者,分析年龄、移植类型等基线特征、临床表现及移植后合并症。

主要发现

  • 305例HHV-6感染患者检测阳性中位时间为移植后20天,15例无症状,其余临床表现发生率由高到低依次为发热、皮疹、腹泻、出血性膀胱炎、血小板延迟植入、中枢神经系统症状、腹痛、肺炎和口周麻木。
  • 189例患者合并急性GVHD,其中45例HHV-6感染发生在急性GVHD之前,120例发生在急性GVHD之后。
  • 45例患者有HHV-6定量检测结果,病毒滴度高低在临床表现中差异无统计学意义。
  • 108例(35.41%)患者存在与其他病毒共激活,包括巨细胞病毒、BK病毒、EB病毒等,其中合并EB病毒激活是影响OS的独立危险因素。
  • 抗病毒治疗组与未抗病毒治疗组HHV-6转阴时间差异无统计学意义[7(5~10)天对8(4~14)天,P=0.199],5年OS率差异也无统计学意义[(82.7±2.6)%对(91.3±3.1)%,χ(2)=3.304,P=0.069]。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to analyze the clinical manifestations of human herpesvirus 6 (HHV-6) infection within 100 days after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and to investigate the association of HHV-6 viral load with clinical outcomes as well as the effect of antiviral treatment on the course of HHV-6 infection. Methods: This retrospective study included patients who tested positive for HHV-6 within 100 days after allo-HSCT at the Peking University Institute of Hematology from February 2016 to February 2023. The study analyzed the patients' baseline characteristics, including age and transplantation type, as well as their clinical manifestations. Additionally, post-transplant complications were examined. Results: This study detected that 305 patients with HHV-6 infection were positive with a median time of 20 days post-transplant. Fifteen patients were asymptomatic, whereas the remaining patients exhibited the following symptoms: fever, rash, diarrhea, hemorrhagic cystitis, delayed platelet engraftment, central nervous system symptoms, abdominal pain, pneumonia and perioral numbness. Acute graft-versus-host disease (aGVHD) was diagnosed in 189 patients, with 45 cases of HHV-6 infection occurring before the onset of aGVHD and 120 cases occurring after aGVHD developed. Quantitative HHV-6 detection was available for 45 patients, and no statistically significant differences were found in the clinical manifestations according to the viral titer. A total of 108 (35.41%) patients experienced coactivation with other viruses, including cytomegalovirus, BK virus, and Epstein-Barr virus (EBV). Notably, coinfection with EBV was determined as an independent risk factor for overall survival (OS). No statistically significant difference in the time to HHV-6 viral clearance was observed between the antiviral treatment and non-treatment groups [7 (5-10) days vs 8 (4-14) days, P=0.199]. Similarly, the 5-year OS rates between the two groups were not significantly different [ (82.7 ± 2.6) % vs (91.3 ± 3.1) %, χ(2)=3.304, P=0.069]. Discussion: The most prevalent clinical manifestations were fever, rash, and diarrhea in patients with HHV-6 infection after allo-HSCT. No significant correlation was found between the severity of the clinical symptoms and the viral titer. Additionally, no significant differences in the time to HHV-6 clearance or 5-year OS were observed between patients who received antiviral treatment and those who did not. 目的: 分析异基因造血干细胞移植(allo-HSCT)后100 d内人类疱疹病毒6型(HHV-6)激活的临床表现,研究HHV-6病毒载量对临床表现的影响及抗病毒治疗对HHV-6激活转归的影响。 方法: 回顾性研究2016年2月至2023年2月在北京大学血液病研究所接受allo-HSCT后100 d内HHV-6阳性的患者,分析患者的年龄、移植类型等基本特征以及临床表现,同时对移植后合并症等情况进行分析。 结果: 研究纳入305例HHV-6感染患者,HHV-6检测阳性中位时间为移植后20 d。有15例患者无症状,其余患者根据临床表现发生率由高到低依次是:发热、皮疹、腹泻、出血性膀胱炎、血小板延迟植入、中枢神经系统症状、腹痛、肺炎和口周麻木。189例患者合并急性GVHD(其中45例HHV-6感染发生在急性GVHD之前,120例HHV-6感染发生在急性GVHD之后)。45例患者有HHV-6定量检测结果,病毒滴度高低在临床表现中差异无统计学意义。108例(35.41%)患者存在与其他病毒共激活情况,合并感染的病毒包括巨细胞病毒、BK病毒、EB病毒等,其中合并EB病毒激活是影响总生存(OS)的独立危险因素。抗病毒治疗与未抗病毒治疗组患者HHV-6转阴时间差异无统计学意义[7(5~10)d对8(4~14)d,P=0.199],5年OS率差异也无统计学意义[(82.7±2.6)%对(91.3±3.1)%,χ(2)=3.304,P=0.069]。 结论: allo-HSCT后HHV-6感染患者临床表现以发热、皮疹和腹泻多见,与病毒滴度高低无明显相关性,且是否抗病毒治疗在HHV-6转阴时间与移植后5年OS率中未见显著性差异。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Huang L, Han TT, Wei FF, et al. [Clinical characteristics of HHV-6 infection after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39746691. doi:10.3760/cma.j.cn121090-20240831-00330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。